Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has announced a decision to execute a simple spin-off (demerger), separating into a surviving entity focused on its CDMO business and a new entity (Samsung Episholdings Co., Ltd., provisional) dedicated to subsidiary management and investments. The surviving entity will undergo a listing change, while the new entity will seek relisting on the KOSPI market, with the spin-off date set for October 1, 2025.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Decision on Corporate Spin-off
- Spin-off Overview:
- Spin-off Method: Simple Spin-off (Demerger) under Articles 530-2 through 530-11 of the Korean Commercial Code
- Surviving Entity: Samsung Biologics Co., Ltd. (CDMO Business Division) – Subject to Listing Change (KOSPI)
- Newly Established Entity: Samsung Episholdings Co., Ltd. (provisional) (Holding & Investment Division managing subsidiaries like Samsung Bioepis) – Subject to Relisting (KOSPI)
- Spin-off Ratio:
- Surviving Entity: 0.6503913
- Newly Established Entity: 0.3496087
- Financial Details (As of March 31, 2025, in KRW):
- Surviving Entity: Total Assets 9,986,729,911,728 / Total Liabilities 3,743,013,838,765 / Total Equity 6,243,716,072,963 / Capital Stock 115,727,377,500
- Newly Established Entity: Total Assets 3,365,179,974,094 / Total Liabilities 8,958,509,056 / Total Equity 3,356,221,465,038 / Capital Stock 62,207,622,500
- Key Schedule:
- Board Resolution Date: May 22, 2025
- Shareholder Record Date: July 29, 2025
- Scheduled EGM Date: September 16, 2025
- Trading Suspension Period: September 29, 2025 – October 28, 2025
- New Share Allotment Record Date: September 30, 2025
- Spin-off Effective Date: October 1, 2025
- Expected Listing Change / Relisting Date: October 29, 2025
- Other Important Details:
- Appraisal Rights: Not applicable due to the nature of a simple spin-off with relisting plans.
- Joint Liability: Both surviving and newly established entities will remain jointly and severally liable for obligations incurred prior to the spin-off.
- Related Disclosure: Response to the KRX inquiry request dated May 21, 2025, regarding spin-off rumors.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Spin-off Execution and EGM Voting Results
This disclosure provides notice of Samsung Biologics’ decision to execute a corporate spin-off plan.
Tracking the EGM voting results on September 16, 2025, and checking the execution of subsequent milestones—such as the trading suspension, listing change, and relisting process—is essential.
Relevant details can be verified in future disclosures regarding EGM outcomes, trading suspension notices, and official listing filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
